RT Journal Article
SR Electronic
T1 QT Interval Prolongation and Torsade De Pointes in Patients with COVID-19 treated with Hydroxychloroquine/Azithromycin
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.27.20074583
DO 10.1101/2020.04.27.20074583
A1 Chorin, Ehud
A1 Wadhwani, Lalit
A1 Magnani, Silvia
A1 Dai, Matthew
A1 Shulman, Eric
A1 Nadeau-Routhier, Charles
A1 Knotts, Robert
A1 Bar-Cohen, Roi
A1 Kogan, Edward
A1 Barbhaiya, Chirag
A1 Aizer, Anthony
A1 Holmes, Douglas
A1 Bernstein, Scott
A1 Spinelli, Michael
A1 Park, David
A1 Stefano, Carugo
A1 Chinitz, Larry
A1 Jankelson, Lior
YR 2020
UL http://medrxiv.org/content/early/2020/05/01/2020.04.27.20074583.abstract
AB Background The emergence of the COVID-19 pandemic has resulted in over two million affected and over 150 thousand deaths to date. There is no known effective therapy for the disease. Initial reports suggesting the potential benefit of Hydroxychloroquine/Azithromycin (HY/AZ) have resulted in massive adoption of this combination worldwide. However, while the true efficacy of this regimen is unknown, initial reports have raised concerns regarding the potential risk of QT prolongation and induction of torsade de pointes (TdP).Methods This is a multicenter retrospective study of 251 patients with COVID-19 treated with HY/AZ. We reviewed ECG tracings from baseline and until 3 days after completion of therapy to determine the progression of QTc and incidence of arrhythmia and mortality.Results QTc prolonged in parallel with increasing drug exposure and incompletely shortened after its completion. Extreme new QTc prolongation to > 500 ms, a known marker of high risk for TdP had developed in 15.9% of patients. One patient developed TdP requiring emergent cardioversion. Seven patients required premature termination of therapy. The baseline QTc of patients exhibiting QTc prolongation of > 60 ms was normal.Conclusion The combination of HY/AZ significantly prolongs the QTc in patients with COVID-19. This prolongation may be responsible for life threating arrhythmia in the form of TdP. This risk mandates careful consideration of HY/AZ therapy in lights of its unproven efficacy. Strict QTc monitoring should be performed if the regimen is given.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNoneAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesdata will be made available as decided by the DSC of the study